WO2000040242A3 - Herstellung eines mittels gegen hepatitis b-, hi-, paramyxo- und orthomyxo-viren - Google Patents

Herstellung eines mittels gegen hepatitis b-, hi-, paramyxo- und orthomyxo-viren Download PDF

Info

Publication number
WO2000040242A3
WO2000040242A3 PCT/EP1999/010463 EP9910463W WO0040242A3 WO 2000040242 A3 WO2000040242 A3 WO 2000040242A3 EP 9910463 W EP9910463 W EP 9910463W WO 0040242 A3 WO0040242 A3 WO 0040242A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
alkyl
cycloalkyl
hydrogen
halogen
Prior art date
Application number
PCT/EP1999/010463
Other languages
English (en)
French (fr)
Other versions
WO2000040242A2 (de
Inventor
Axel Ullrich
Original Assignee
Axxima Pharmaceuticals Ag
Axel Ullrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axxima Pharmaceuticals Ag, Axel Ullrich filed Critical Axxima Pharmaceuticals Ag
Priority to AU25400/00A priority Critical patent/AU2540000A/en
Publication of WO2000040242A2 publication Critical patent/WO2000040242A2/de
Publication of WO2000040242A3 publication Critical patent/WO2000040242A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Verwendung einer Substanz der allgemeinen Formel (I), worin (A) R1 und R2 jeweils Wasserstoff sind, R3 ein Halogen, -CF3, Alkoxy mit 1 oder 2 Kohlenstoffatomen oder ein halogensubstituiertes Alkoxy mit 1 oder 2 Kohlenstoffatomen ist, und R4 Alkyl mit 1 bis 4 Kohlenstoffatomen oder Cycloalkyl mit 3 oder 4 Kohlenstoffatomen ist; (B) R1 Wasserstoff ist und R2 und R3, die gleich oder unterschiedlich sind, ein Halogen oder -CF3 sind, und R4 Alkyl mit 1 bis 4 Kohlenstoffatomen oder Cycloalkyl mit 3 oder 4 Kohlenstoffatomen ist; (C) R1 Wasserstoff ist, R2 Alkyl mit 1 oder 2 Kohlenstoffatomen ist, R3 ein Halogen ist und R4 Alkyl mit 1 bis 4 Kohlenstoffatomen oder Cycloalkyl mit 3 oder 4 Kohlenstoffatomen ist; (D) R1 Wasserstoff ist, R2 und R3 zusammen 3',4'-Methylendioxy sind und R4 Alkyl mit 1 bis 4 Kohlenstoffatomen oder Cycloalkyl mit 3 oder 4 Kohlenstoffatomen ist; oder eines Derivas davon mit offenem Isoxazolring oder eines physiologisch verträglichen Salzes davon, zur Herstellung eines Mittels zur Prävention oder Behandlung von Virusinfektionen durch Hepatitis-B-Viren, HI-Viren, Viren der Paramyxogruppe oder/und der Orthomyxogruppe.
PCT/EP1999/010463 1998-12-30 1999-12-29 Herstellung eines mittels gegen hepatitis b-, hi-, paramyxo- und orthomyxo-viren WO2000040242A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25400/00A AU2540000A (en) 1998-12-30 1999-12-29 Production of an agent acting against hepatitis b, hi, paramyxo- and orthomyxoviruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19860802A DE19860802A1 (de) 1998-12-30 1998-12-30 Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren
DE19860802.0 1998-12-30

Publications (2)

Publication Number Publication Date
WO2000040242A2 WO2000040242A2 (de) 2000-07-13
WO2000040242A3 true WO2000040242A3 (de) 2000-11-16

Family

ID=7893172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/010463 WO2000040242A2 (de) 1998-12-30 1999-12-29 Herstellung eines mittels gegen hepatitis b-, hi-, paramyxo- und orthomyxo-viren

Country Status (3)

Country Link
AU (1) AU2540000A (de)
DE (1) DE19860802A1 (de)
WO (1) WO2000040242A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021160A2 (en) * 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
CA2494164A1 (en) 2002-08-23 2004-03-04 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection
WO2004099164A1 (en) * 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection
US7326790B2 (en) 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
WO2005049065A2 (en) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
US20060024376A1 (en) * 2004-07-30 2006-02-02 The University Of Chicago Methods and compositions for reducing toxicity associated with leflunomide treatment
WO2007027230A2 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
TWI530286B (zh) * 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607775A2 (de) * 1993-01-08 1994-07-27 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
EP0649660A2 (de) * 1993-10-26 1995-04-26 Hoechst Aktiengesellschaft Pharmazeutische Zubereitung für die parenterale, enterale und dermale Verabreichung von praktisch unlöslichen Arzneistoffen und Verfahren zu ihrer Herstellung
EP0821960A1 (de) * 1996-07-31 1998-02-04 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Modulation der Apoptose
EP0821952A1 (de) * 1996-07-31 1998-02-04 Hoechst Aktiengesellschaft Verwendung von isoxazol- und Crotonsäureamidderivaten zur Modulation der Apoptose

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607775A2 (de) * 1993-01-08 1994-07-27 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
EP0649660A2 (de) * 1993-10-26 1995-04-26 Hoechst Aktiengesellschaft Pharmazeutische Zubereitung für die parenterale, enterale und dermale Verabreichung von praktisch unlöslichen Arzneistoffen und Verfahren zu ihrer Herstellung
EP0821960A1 (de) * 1996-07-31 1998-02-04 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Modulation der Apoptose
EP0821952A1 (de) * 1996-07-31 1998-02-04 Hoechst Aktiengesellschaft Verwendung von isoxazol- und Crotonsäureamidderivaten zur Modulation der Apoptose

Also Published As

Publication number Publication date
AU2540000A (en) 2000-07-24
DE19860802A1 (de) 2000-10-26
WO2000040242A2 (de) 2000-07-13

Similar Documents

Publication Publication Date Title
TR200300544T1 (tr) Erimiş siklik bileşimler ve tıbbi kullanımları
AU4306796A (en) Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs
TW427887B (en) Pharmaceutical composition comprising a benzimidazole derivative for treating viral infections
NL300344I1 (nl) Nucleotide-analogen
MX9504349A (es) Derivados de aroilpiperidina.
ES2137169T3 (es) Nuevos derivados de tiazolilbenzofurano, procedimientos para su preparacion y composicion farmaceutica que los contiene.
BR9916772A (pt) Quinolinacarboxamidas como agentes antivirais
WO2000040242A3 (de) Herstellung eines mittels gegen hepatitis b-, hi-, paramyxo- und orthomyxo-viren
AU4705300A (en) Cosmetic compositions
HK1072770A1 (en) Bicyclic compound
EP1340755A4 (de) Mittel mit wirkung gegen helicobacter
CA2336412A1 (en) Medicament for treatment of diabetes
NZ503912A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists
TR200003414T2 (tr) Anti-viral terkipler
CA2168937A1 (en) Anti-neurodegeneratively active 10-aminoaliphatyl-dibenz[b,f]oxepines
BR0213465A (pt) Compostos de 4-imidazolin-2-ona
NZ505543A (en) N-[cis-2-(6-halo, 2-hydroxy, 3-propionylphenyl)-cyclopropyl]-N'-pyrid-2-yl-urea derivatives and salts, prodrugs, pharmaceuticals thereof; useful for the treatment or prophylaxis of HIV
PT1628968E (pt) Compostos de 4-imidazolin-2-ona
DE60005517D1 (de) Kaliumkanal-blockierende mittel
BR0213550A (pt) Composição anti-helmìntica
TW334337B (en) Preparation and composition for a compound of controlling and preventing phytopathogenic fungi
MY136928A (en) New isoquinoline compounds, a process for their preparation and pharmaceutical composition containing them
NZ246598A (en) Trazodone derivatives; compounds and preparation, pharmaceutical compositions; intermediate compounds
BR9915441A (pt) Compostos funcionais de carbamato particulado e revestimentos em pó compreendendo os mesmos
AU657423B2 (en) Novel piperidine derivatives and process for preparation thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase